Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cardiac patients of NYHA Class II to III~* ASA class maximally 4~* Age at least 18~* Scheduled for elective, non-cardiac surgery under general anesthesia with propofol in the supine position, with planned muscle relaxation using rocuronium and allowing for 12-lead ECG assessment during surgery;~* Given written informed consent.~Exclusion Criteria:~* Disorders interfering with the reliability of the assessments (e.g. ECG measurements), such as paroxysmal atrial fibrillation or the presence of a pacemaker~* Known or suspected neuromuscular disorders impairing NMB~* Known or suspected significant renal dysfunction~* Known or suspected (family) history of malignant hyperthermia~* Known or suspected allergy to narcotics, muscle relaxants or other medication used during general anesthesia~* Intended) use of medication expected to interfere with the effect of rocuronium as given in this trial, based on the dose and/or the time of administration (such as antibiotics, anticonvulsants and Mg2+ )~* Pregnancy (pregnancy to be excluded for women both from medical history and by an hCG test within 24 h before surgery, except for women who were not of childbearing potential, i.e. at least 2 years menopausal or have undergone tubal ligation or a hysterectomy)~* Childbearing potential without using any method of birth control or using only hormonal contraception as birth control (subjects were allowed to participate if they were willing to use a condom, or a diaphragm with spermicide, or IUD, or have a vasectomized partner (\>6 months) or abstinence, for one month after participation in the trial)~* Breast -feeding~* Prior participation in any trial with Org 25969~* Participation in another clinical trial not pre -approved by Organon, within 30 days of entering into trial 19.4.309

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Sugammadex 2.0 mg/kg
- Arm 2 (Type: EXPERIMENTAL): Sugammadex 4.0 mg/kg
- Arm 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).